Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia.
The last earnings update was 42 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Cleveland BioLabs is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cleveland BioLabs has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Cleveland BioLabs. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Cleveland BioLabs's earnings available for a low price, and how does
this compare to other companies in the same industry?
Cleveland BioLabs has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Examine Cleveland BioLabs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Cleveland BioLabs's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cleveland BioLabs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Cleveland BioLabs's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Cleveland BioLabs's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Cleveland BioLabs's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Cleveland BioLabs is high growth as no earnings estimate data is available.
Unable to determine if Cleveland BioLabs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Cleveland BioLabs's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Cleveland BioLabs's finances.
The net worth of a company is the difference between its assets and liabilities.
Cleveland BioLabs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Cleveland BioLabs's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Cleveland BioLabs's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Cleveland BioLabs has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Yakov N. Kogan, Ph.D., MBA co-founded Cleveland Biolabs, Inc. in 2000 and has been its Chief Executive Officer since June 14, 2012 and serves as its interim Principal Financial Officer since June 16, 2017 and also serves as its Secretary. Dr. Kogan serves as an Executive Vice President of Business Development and Secretary of Taiwan Indigena Botanica Co., Ltd. (formerly, Mega Biotech & Electronics Co., Ltd.). He served as Interim Chief Executive Officer of Cleveland Biolabs from January 2012 to June 14, 2012 and served as its Chief Operating Officer from February 8, 2008 to January 2012. He served as Secretary of Cleveland Biolabs, Inc., from March 2006 to June 2012 and served as its Executive Vice President of Business Development from June 2003 to February 2008. He served as Vice President of Research and Development and Product Marketing at Digital Fuel Technologies. Prior to co-founding Digital Fuel Technologies in 2000, Dr. Kogan led large development projects for the wireless communications industry at Amdocs. For seven years prior to Amdocs, he managed large-scale development projects for major Israeli banks, including Leumi Bank, Discount Bank and Post Bank. From 2001 to 2004, he served as Director for Business Development at Integrated Genomics, Inc. (Chicago, IL), a world leader in comparative genomics and applied bioinformatics, where he was responsible for commercial sales and expansion of its capital base. Prior to his tenure in business development, Dr. Kogan served as a Group Leader and Senior Scientist at Integrated Genomics, Inc. and ThermoGen, Inc. (Chicago, IL) and as Research Associate at the University of Chicago. Dr. Kogan previously worked at Integrated Genomics where he ran production units, as well as negotiated multi-million-dollar research contracts. He has more than 10 years of experience in biology and biotechnology. He served as a Director of Cleveland Biolabs, Inc. since June 2003. He serves as a Director at Russian Pharmaceutical Company Incuron, LLC and Taiwan Indigena Botanica Co., Ltd. He served as Director of Digital Fuel Technologies, Inc. He has published many research papers on data integration, query languages for XML and DBMS for semi-structured data. He holds a B.S. (cum laude) and M.S. in Computer Science from Hebrew University. Dr. Kogan holds Ph.D. degree in Molecular Biology from All-Union Research Institute of Genetics and Selection of Industrial Microorganisms (VNII Genetica), as well as M.S. in Biology from the Moscow State University. He holds an MBA degree from the University of Chicago Graduate School Of Business.
Yakov's compensation has been consistent with company performance over the past year.
Yakov's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Cleveland BioLabs management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO, Interim Principal Financial Officer & Secretary
President & Chief Medical Officer
Chief Scientific Officer
Executive Vice President of Regulatory Affairs
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Cleveland BioLabs board of directors is less than 3 years, this suggests a new board.
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company’s product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.